117 related articles for article (PubMed ID: 33560702)
1. Impact of Baseline Corticosteroids on Immunotherapy Efficacy in Patients With Advanced Melanoma.
Kartolo A; Deluce J; Holstead R; Hopman W; Lenehan J; Baetz T
J Immunother; 2021 May; 44(4):167-174. PubMed ID: 33560702
[TBL] [Abstract][Full Text] [Related]
2. Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.
Arbour KC; Mezquita L; Long N; Rizvi H; Auclin E; Ni A; Martínez-Bernal G; Ferrara R; Lai WV; Hendriks LEL; Sabari JK; Caramella C; Plodkowski AJ; Halpenny D; Chaft JE; Planchard D; Riely GJ; Besse B; Hellmann MD
J Clin Oncol; 2018 Oct; 36(28):2872-2878. PubMed ID: 30125216
[TBL] [Abstract][Full Text] [Related]
3. The impact of corticosteroid use during anti-PD1 treatment.
Pan EY; Merl MY; Lin K
J Oncol Pharm Pract; 2020 Jun; 26(4):814-822. PubMed ID: 31495293
[TBL] [Abstract][Full Text] [Related]
4. Immune Checkpoint Inhibitor Outcomes for Patients With Non-Small-Cell Lung Cancer Receiving Baseline Corticosteroids for Palliative Versus Nonpalliative Indications.
Ricciuti B; Dahlberg SE; Adeni A; Sholl LM; Nishino M; Awad MM
J Clin Oncol; 2019 Aug; 37(22):1927-1934. PubMed ID: 31206316
[TBL] [Abstract][Full Text] [Related]
5. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
[TBL] [Abstract][Full Text] [Related]
6. Comparative effectiveness of second-line ipilimumab vs. nivolumab in combination with ipilimumab in patients with advanced melanoma who received frontline anti-PD-1 antibodies.
Baron K; Moser JC; Patel S; Grossmann KF; Colonna SV; Hyngstrom JR
J Oncol Pharm Pract; 2021 Apr; 27(3):555-559. PubMed ID: 32423325
[TBL] [Abstract][Full Text] [Related]
7. Clinical Response to Immunotherapy Targeting Programmed Cell Death Receptor 1/Programmed Cell Death Ligand 1 in Patients With Treatment-Resistant Microsatellite Stable Colorectal Cancer With and Without Liver Metastases.
Wang C; Sandhu J; Ouyang C; Ye J; Lee PP; Fakih M
JAMA Netw Open; 2021 Aug; 4(8):e2118416. PubMed ID: 34369992
[TBL] [Abstract][Full Text] [Related]
8. Predictors of immunotherapy-induced immune-related adverse events.
Kartolo A; Sattar J; Sahai V; Baetz T; Lakoff JM
Curr Oncol; 2018 Oct; 25(5):e403-e410. PubMed ID: 30464691
[TBL] [Abstract][Full Text] [Related]
9. Novel PD-1 inhibitor prolgolimab: expanding non-resectable/metastatic melanoma therapy choice.
Tjulandin S; Demidov L; Moiseyenko V; Protsenko S; Semiglazova T; Odintsova S; Zukov R; Lazarev S; Makarova Y; Nechaeva M; Sakaeva D; Andreev A; Tarasova A; Fadeyeva N; Shustova M; Kuryshev I
Eur J Cancer; 2021 May; 149():222-232. PubMed ID: 33872982
[TBL] [Abstract][Full Text] [Related]
10. Ipilimumab alone or ipilimumab plus anti-PD-1 therapy in patients with metastatic melanoma resistant to anti-PD-(L)1 monotherapy: a multicentre, retrospective, cohort study.
Pires da Silva I; Ahmed T; Reijers ILM; Weppler AM; Betof Warner A; Patrinely JR; Serra-Bellver P; Allayous C; Mangana J; Nguyen K; Zimmer L; Trojaniello C; Stout D; Lyle M; Klein O; Gerard CL; Michielin O; Haydon A; Ascierto PA; Carlino MS; Lebbe C; Lorigan P; Johnson DB; Sandhu S; Lo SN; Blank CU; Menzies AM; Long GV
Lancet Oncol; 2021 Jun; 22(6):836-847. PubMed ID: 33989557
[TBL] [Abstract][Full Text] [Related]
11. PD-L1 expression and outcome of advanced melanoma patients treated with anti-PD-1/PD-L1 agents: a meta-analysis.
Abdel-Rahman O
Immunotherapy; 2016 Sep; 8(9):1081-9. PubMed ID: 27485080
[TBL] [Abstract][Full Text] [Related]
12. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and theranostic 18F-FDG PET biomarkers for anti-PD1 immunotherapy in metastatic melanoma: association with outcome and transcriptomics.
Seban RD; Nemer JS; Marabelle A; Yeh R; Deutsch E; Ammari S; Moya-Plana A; Mokrane FZ; Gartrell RD; Finkel G; Barker L; Bigorgne AE; Schwartz LH; Saenger Y; Robert C; Dercle L
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2298-2310. PubMed ID: 31346755
[TBL] [Abstract][Full Text] [Related]
14. Radiological dynamics and SITC-defined resistance types of advanced melanoma during anti-PD-1 monotherapy: an independent single-blind observational study on an international cohort.
Bai X; Kim M; Kasumova G; Si L; Tang B; Cui C; Yang X; Wei X; Cohen J; Lawrence D; Freedman C; Fadden R; Rubin K; Sharova T; Frederick D; Flaherty K; Sullivan R; Guo J; Boland G
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33632901
[TBL] [Abstract][Full Text] [Related]
15. Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy.
Dupuis F; Lamant L; Gerard E; Torossian N; Chaltiel L; Filleron T; Beylot-Barry M; Dutriaux C; Prey S; Gros A; Jullie ML; Meyer N; Vergier B
Br J Cancer; 2018 Jul; 119(2):193-199. PubMed ID: 29973670
[TBL] [Abstract][Full Text] [Related]
16. Toxicity and efficacy of Gamma Knife radiosurgery for brain metastases in melanoma patients treated with immunotherapy or targeted therapy-A retrospective cohort study.
Gatterbauer B; Hirschmann D; Eberherr N; Untersteiner H; Cho A; Shaltout A; Göbl P; Fitschek F; Dorfer C; Wolfsberger S; Kasprian G; Höller C; Frischer JM
Cancer Med; 2020 Jun; 9(11):4026-4036. PubMed ID: 32249551
[TBL] [Abstract][Full Text] [Related]
17. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of late concurrent hypofractionated radiotherapy in advanced melanoma patients failing anti-PD-1 monotherapy.
Funck-Brentano E; Baghad B; Fort M; Aouidad I; Roger A; Beauchet A; Otmezguine Y; Blom A; Longvert C; Boru B; Saiag P
Int J Cancer; 2020 Sep; 147(6):1707-1714. PubMed ID: 32083739
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy With Programmed Cell Death 1 Inhibitors for 5 Patients With Conjunctival Melanoma.
Sagiv O; Thakar SD; Kandl TJ; Ford J; Sniegowski MC; Hwu WJ; Esmaeli B
JAMA Ophthalmol; 2018 Nov; 136(11):1236-1241. PubMed ID: 30352118
[TBL] [Abstract][Full Text] [Related]
20. Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG.
Knispel S; Stang A; Zimmer L; Lax H; Gutzmer R; Heinzerling L; Weishaupt C; Pföhler C; Gesierich A; Herbst R; Kaehler KC; Weide B; Berking C; Loquai C; Utikal J; Terheyden P; Kaatz M; Schlaak M; Kreuter A; Ulrich J; Mohr P; Dippel E; Livingstone E; Becker JC; Weichenthal M; Chorti E; Gronewold J; Schadendorf D; Ugurel S
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32371460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
